Adaptimmune’s Tecelra Becomes First FDA-Approved Engineered Cell Therapy for Solid Tumors

Approved under the regulator’s accelerated pathway, Tecelra is also the first new synovial sarcoma therapy in more than a decade, according to Adaptimmune Therapeutics.